Regeneron Pharmaceuticals is trading at $756.09, down 4.05%, amid broader risk-off pressure from renewed geopolitical tension, higher oil prices and rising Treasury yields.
- No clear Regeneron-specific catalyst surfaced in the available September 28 reporting.
- Bloomberg reported U.S. stocks falling alongside Treasuries as oil prices climbed and inflation concerns returned.
- Available evidence points to a macro backdrop rather than a company-specific explanation for the decline.